Guidelines for choice of selective serotonin reuptake inhibitor in depressive illness

Advances in Psychiatric Treatment

Volumn 7, Issue 3, 2001, Pages 170-180

  Anderson, I M ^a   Edwards, J G ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; CITALOPRAM; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; FLUOXETINE; FLUVOXAMINE; NEUROLEPTIC AGENT; NORFLUOXETINE; OPIATE DERIVATIVE; PAROXETINE; PHENYTOIN; SEROTONIN; SEROTONIN 2C RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; BREAST FEEDING; CLINICAL RESEARCH; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DEPRESSION; DOSE RESPONSE; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; HEALTH CARE QUALITY; HUMAN; OUTCOMES RESEARCH; PHARMACOLOGICAL PROCEDURES; PRACTICE GUIDELINE; PREGNANCY; PRESCRIPTION; QUALITY CONTROL; SIDE EFFECT; UNITED KINGDOM;

EID: 0034810244     PISSN: 13555146     EISSN: None     Source Type: Journal    
DOI: 10.1192/apt.7.3.170     Document Type: Article

References (39)

1. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 1993 British Association for Psychopharmacology Guidelines
2. Comparative efficacy and tolerability among different selective serotonin re-uptake inhibitors and venlafaxine in a naturalistic setting
3. Acute fluoxetine overdose: A report of 234 cases
4. Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression. A 6-month double-blind study in a primary-care setting in France
5. British National Formulary
6. Absenteeism among employees treated for depression
7. Selective serotonin reuptake inhibitor treatment in the UK: Risk of relapse or recurrence of depression
8. Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness
9. Systematic review and guide to selection of selective serotonin reuptake inhibitors
10. Drug safety monitoring of 12692 patients treated with fluoxetine
11. Fluoxetine versus sertraline and paroxetine in major depression: Long-term changes in weight
12. Citalopram toxicity
13. A review of the safety of selective serotonin reuptake inhibitors during pregnancy
14. Selective serotonin reuptake inhibitors in affective disorders. I. Basic pharmacology
15. Selective serotonin reuptake inhibitors in affective disorders. II. Efficacy and quality of life
16. Selective serotonin reuptake inhibitor dose titration in the naturalistic setting
17. A rating scale for depression
18. Overdose and safety with fluvoxamine
19. Relative mortality from overdose of antidepressants
20. Antidepressant use in the psychiatrist setting in Austria: A comparison of citalopram, fluoxetine, and paroxetine
21. SSRI antidepressant use patterns and their relation to clinical global impression scores: A naturalistic study
22. Risks with citalopram in perspective
23. Analysis of sertraline-only overdoses
24. The treatment of depression in UK general practice: Selective serotonin reuptake inhibitors and tricyclic antidepressants compared
25. A comparison if fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies
26. Newer antidepressants: A comparison of tolerability in general practice
27. Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial
28. SSRI-induced sexual dysfunction: Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients
29. Double-blind multicenter comparison of fluvoxamine verus sertraline in the treatment of depressed outpatients
30. Fatal overdose with citalopram
31. Citalopram overdose - Review of cases treated in Swedish hospitals
32. Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial
33. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline
34. Antidepressant pharmacotherapy: Economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization
35. Economic appraisal of citalopram in the management of single-episode depression
36. Emergence of intense suicidal preoccupation during fluoxetine treatment
37. Effect of SSRI antidepressants on ejaculation: A double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline
38. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England
39. Psychotropic drugs in mother's milk: A comprehensive review of assay methods, pharmacokinetics and of safety in breastfeeding